Joey CohenMedication Adherence
Pat PurcellMeeting Engagement
Frank BurrellScientific Storytelling
Brenda SnowAuthentic Patient Voice
Liz KaneImpactful Strategy
Matt TurnerPatient Affordability
Amy GilesIncreasing Engagement
Matthew DurhamOmnidynamic Marketing
Bud BilanichSuccess Coach
Paul TheisenPatient Acquisition
David LinetskyPoint-of-Care Marketing
Stacey GandlerBrand Nourishment
Daniel SontupeMarket Access
Suma Ramadas, PhDMedical Affairs
In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared ...
Username
Email
Password
Confirm Password
Remember Me
Username or Email
